NO964650L - LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff - Google Patents
LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoffInfo
- Publication number
- NO964650L NO964650L NO19964650A NO964650A NO964650L NO 964650 L NO964650 L NO 964650L NO 19964650 A NO19964650 A NO 19964650A NO 964650 A NO964650 A NO 964650A NO 964650 L NO964650 L NO 964650L
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- lag
- protein
- soluble polypeptide
- idiotype antibody
- Prior art date
Links
- 102000017578 LAG3 Human genes 0.000 title abstract 3
- 101150030213 Lag3 gene Proteins 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 230000003302 anti-idiotype Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9405643 | 1994-05-06 | ||
PCT/FR1995/000593 WO1995030750A2 (fr) | 1994-05-06 | 1995-05-05 | Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype |
Publications (3)
Publication Number | Publication Date |
---|---|
NO964650D0 NO964650D0 (no) | 1996-11-04 |
NO964650L true NO964650L (no) | 1997-01-06 |
NO325828B1 NO325828B1 (no) | 2008-07-28 |
Family
ID=9463004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19964650A NO325828B1 (no) | 1994-05-06 | 1996-11-04 | Anvendelse av et antistoff dannet mot et antigen. |
Country Status (18)
Country | Link |
---|---|
US (3) | US5955300A (no) |
EP (1) | EP0758383B1 (no) |
JP (1) | JP3700859B2 (no) |
KR (1) | KR100257466B1 (no) |
CN (1) | CN1110557C (no) |
AT (1) | ATE352617T1 (no) |
BR (1) | BR9507618A (no) |
CA (1) | CA2189657C (no) |
DE (1) | DE69535375T2 (no) |
DK (1) | DK0758383T3 (no) |
ES (1) | ES2281899T3 (no) |
IL (1) | IL113617A (no) |
MX (1) | MX9605365A (no) |
NO (1) | NO325828B1 (no) |
PT (1) | PT758383E (no) |
RU (1) | RU2178306C2 (no) |
WO (1) | WO1995030750A2 (no) |
ZA (1) | ZA953629B (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69624824T2 (de) * | 1995-07-21 | 2003-09-11 | Applied Research Systems Ars Holding N.V., Curacao | Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein |
ATE320488T1 (de) * | 1996-11-28 | 2006-04-15 | Roussy Inst Gustave | Mutanten des lag-3 proteins, ihre expression und verwendung |
CA2272130C (en) * | 1996-11-29 | 2007-10-23 | Applied Research Systems Ars Holding N.V. | Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3) |
EP0900841A1 (en) * | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
EP0893507A1 (en) | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6660843B1 (en) † | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6434012B2 (en) * | 2000-02-11 | 2002-08-13 | Tyco Electronics Logistics Ag | Circuit board interconnect |
WO2001083525A2 (en) * | 2000-05-03 | 2001-11-08 | Amgen Inc. | Modified peptides, comprising an fc domain, as therapeutic agents |
EP2388265A1 (en) * | 2002-02-22 | 2011-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1897548B2 (en) | 2003-02-28 | 2024-05-22 | The Johns Hopkins University | T cell regulation |
FR2868781B1 (fr) * | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
EP3508502B1 (en) | 2013-09-20 | 2023-04-26 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
CN108064242B (zh) | 2014-05-28 | 2022-10-21 | 阿吉纳斯公司 | 抗gitr抗体和其使用方法 |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
WO2017009843A2 (en) | 2015-07-16 | 2017-01-19 | Biokine Therapeutics Ltd. | Compositions, articles of manufacture and methods for treating cancer |
SI3456346T1 (sl) | 2015-07-30 | 2021-11-30 | Macrogenics, Inc. | Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh |
WO2017025871A1 (en) | 2015-08-07 | 2017-02-16 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
SI3376857T1 (sl) * | 2015-11-20 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Nehumane živali, ki imajo humaniziran gen 3 za aktivacijo limfocitov |
WO2017096179A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
GEP20217328B (en) | 2015-12-14 | 2021-12-10 | Macrogenics Inc | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof |
EP3399989B1 (en) | 2015-12-16 | 2023-08-09 | Merck Sharp & Dohme LLC | Anti-lag3 antibodies and antigen-binding fragments |
CA3012833A1 (en) * | 2016-02-04 | 2017-08-10 | Trianni, Inc. | Enhanced production of immunoglobulins |
AU2017281830B2 (en) | 2016-06-20 | 2023-04-06 | Kymab Limited | Anti-PD-L1 antibodies |
ES2915410T3 (es) | 2016-06-23 | 2022-06-22 | Jiangsu Hengrui Medicine Co | Anticuerpo contra LAG-3, fragmento de unión a antígeno del mismo y aplicación farmacéutica del mismo |
CN110023337B (zh) | 2016-10-11 | 2024-01-05 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
BR112019006876A2 (pt) * | 2016-10-13 | 2019-06-25 | Symphogen As | anticorpos e composições anti-lag-3 |
WO2018083087A2 (en) | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Binding proteins |
SG11201907208XA (en) | 2017-02-10 | 2019-09-27 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
JP2020513009A (ja) | 2017-04-05 | 2020-04-30 | シムフォゲン・アクティーゼルスカブSymphogen A/S | Pd−1、tim−3、およびlag−3を標的とする併用治療 |
WO2018208868A1 (en) * | 2017-05-10 | 2018-11-15 | Smet Pharmaceutical Inc | Human monoclonal antibodies against lag3 and uses thereof |
CN110720039A (zh) | 2017-05-30 | 2020-01-21 | 百时美施贵宝公司 | Lag-3阳性肿瘤的治疗 |
JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
JP2020536495A (ja) | 2017-08-30 | 2020-12-17 | フェインズ セラピューティクス,インコーポレーテッド | 抗lag−3抗体及びその使用 |
TW201927337A (zh) * | 2017-12-22 | 2019-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種lag-3抗體醫藥組成物及其用途 |
MA55965A (fr) | 2019-05-13 | 2022-03-23 | Regeneron Pharma | Combinaison d'inhibiteurs pd-1 et d'inhibiteurs lag-3 pour une efficacité améliorée dans le traitement du cancer |
CN112010972B (zh) * | 2019-05-31 | 2023-01-10 | 瑞阳(苏州)生物科技有限公司 | 与人lag-3蛋白结合的抗体及其编码基因和应用 |
CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0325224B1 (en) | 1988-01-22 | 1996-07-31 | ZymoGenetics, Inc. | Methods of producing secreted receptor analogs |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
JPH06508501A (ja) * | 1990-07-02 | 1994-09-29 | ブリストル―マイアーズ スクイブ カンパニー | B細胞上のcd28レセプターに対するリガンドおよび該リガンドを用いた細胞間相互作用の調節方法 |
-
1995
- 1995-05-05 KR KR1019960706281A patent/KR100257466B1/ko not_active IP Right Cessation
- 1995-05-05 US US08/737,271 patent/US5955300A/en not_active Ceased
- 1995-05-05 DK DK95920125T patent/DK0758383T3/da active
- 1995-05-05 BR BR9507618A patent/BR9507618A/pt not_active IP Right Cessation
- 1995-05-05 ZA ZA953629A patent/ZA953629B/xx unknown
- 1995-05-05 MX MX9605365A patent/MX9605365A/es active IP Right Grant
- 1995-05-05 WO PCT/FR1995/000593 patent/WO1995030750A2/fr active IP Right Grant
- 1995-05-05 JP JP52872995A patent/JP3700859B2/ja not_active Expired - Lifetime
- 1995-05-05 EP EP95920125A patent/EP0758383B1/fr not_active Expired - Lifetime
- 1995-05-05 PT PT95920125T patent/PT758383E/pt unknown
- 1995-05-05 CN CN95193718A patent/CN1110557C/zh not_active Expired - Lifetime
- 1995-05-05 DE DE69535375T patent/DE69535375T2/de not_active Expired - Lifetime
- 1995-05-05 CA CA002189657A patent/CA2189657C/fr not_active Expired - Lifetime
- 1995-05-05 US US09/931,103 patent/USRE38313E1/en not_active Expired - Lifetime
- 1995-05-05 IL IL113617A patent/IL113617A/en not_active IP Right Cessation
- 1995-05-05 AT AT95920125T patent/ATE352617T1/de active
- 1995-05-05 ES ES95920125T patent/ES2281899T3/es not_active Expired - Lifetime
- 1995-05-05 RU RU96123299/14A patent/RU2178306C2/ru active
-
1996
- 1996-11-04 NO NO19964650A patent/NO325828B1/no not_active IP Right Cessation
-
1998
- 1998-04-13 US US09/058,555 patent/US6143273A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5955300A (en) | 1999-09-21 |
ES2281899T3 (es) | 2007-10-01 |
KR100257466B1 (ko) | 2000-07-01 |
IL113617A (en) | 2007-09-20 |
CA2189657C (fr) | 2002-03-12 |
BR9507618A (pt) | 1997-08-19 |
CN1110557C (zh) | 2003-06-04 |
AU708825B2 (en) | 1999-08-12 |
KR970702917A (ko) | 1997-06-10 |
PT758383E (pt) | 2007-05-31 |
RU2178306C2 (ru) | 2002-01-20 |
DK0758383T3 (da) | 2007-05-29 |
ATE352617T1 (de) | 2007-02-15 |
WO1995030750A2 (fr) | 1995-11-16 |
CN1155904A (zh) | 1997-07-30 |
WO1995030750A3 (fr) | 1995-12-21 |
MX9605365A (es) | 1997-12-31 |
EP0758383B1 (fr) | 2007-01-24 |
IL113617A0 (en) | 1995-08-31 |
NO964650D0 (no) | 1996-11-04 |
AU2570195A (en) | 1995-11-29 |
JPH09508023A (ja) | 1997-08-19 |
DE69535375T2 (de) | 2007-11-08 |
WO1995030750A8 (fr) | 1999-07-29 |
USRE38313E1 (en) | 2003-11-11 |
EP0758383A1 (fr) | 1997-02-19 |
DE69535375D1 (de) | 2007-03-15 |
NO325828B1 (no) | 2008-07-28 |
JP3700859B2 (ja) | 2005-09-28 |
US6143273A (en) | 2000-11-07 |
ZA953629B (en) | 1996-11-05 |
CA2189657A1 (fr) | 1995-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO964650D0 (no) | LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff | |
BG102983A (en) | Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application | |
BG104149A (en) | Interleukin-18-binding proteins, methods for their preparation and administration | |
ATE430801T1 (de) | Von wd-40 abstammende peptide und ihre verwendung | |
DE69738432D1 (de) | Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven | |
ATE425181T1 (de) | Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate | |
NZ500253A (en) | Osteoprotegerin binding proteins and receptors | |
ATE404583T1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
DK1129186T3 (da) | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet | |
YU79491A (sh) | Varijantni cd44-površinski proteini, dna-sekvence koje ih kodiraju i antitela protiv ovih proteina | |
DE69926627D1 (de) | Insulinartigen wachstumsfaktor bindendes protein -3 variante | |
DE69715181D1 (de) | Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator | |
EP0992584A3 (en) | Purified mammalian FLT3 ligands and agonists and antagonists thereof | |
DE69607034D1 (de) | Pcna bindende substanz | |
DE69333952D1 (de) | Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen. | |
ATE432287T1 (de) | Peptidfragmente mit den zelltod verhindernder aktivität | |
ATE165619T1 (de) | Rekombinante antikörper an der oberfläche von e.coli | |
PT773999E (pt) | Receptor orfao or-1 pertencente a familia de receptores nucleares | |
DE59813388D1 (de) | Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 von Cytomegalovirus und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
MK1K | Patent expired |